GO:0032743 positive regulation of interleukin-2 production: Immune Activation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032743 describes any process that activates or increases the frequency, rate, or extent of interleukin-2 (IL-2) production.
• IL-2 is a critical T cell growth factor, and its positive regulation is central to T cell expansion, effector function, and tolerance.
• Key positive regulators include NF-κB, NFAT, AP-1, and mTOR signaling, while negative regulators such as TIM-3 and BLIMP1 suppress IL-2 production.
• Dysregulated IL-2 production is implicated in autoimmunity, cancer, and chronic infections, making it a therapeutic target.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of genes controlling IL-2 production.
• Understanding this GO term aids in engineering T cells for immunotherapy and identifying biomarkers for immune-related diseases.
Description
Interleukin-2 (IL-2) is a pleiotropic cytokine produced primarily by activated CD4+ T cells and, to a lesser extent, CD8+ T cells, NK cells, and dendritic cells. It plays a central role in T cell proliferation, survival, and effector differentiation. The Gene Ontology term GO:0032743, positive regulation of interleukin-2 production, encompasses all molecular events that increase the frequency, rate, or extent of IL-2 synthesis and secretion. This process is tightly controlled at transcriptional, post-transcriptional, and signaling levels, and its dysregulation contributes to autoimmune diseases, immunodeficiency, and cancer. Researchers study positive regulation of IL-2 production to understand how immune responses are initiated and sustained. For example, IL-2 signaling through the aryl hydrocarbon receptor regulates CD8+ T cell exhaustion, a key factor in cancer immunotherapy. Additionally, IL-2-mediated NF-κB-dependent mRNA splicing modulates interferon gamma production, linking IL-2 to broader cytokine networks. The term is also relevant to CAR-T cell therapies, where CAR-negative T cells can influence IL-2 production and overall efficacy. This article provides a comprehensive overview of GO:0032743, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental methods for study. It is intended for researchers seeking to manipulate IL-2 production for therapeutic or basic science purposes.
positive regulation of interleukin-2 production At A Glance
| GO ID | GO:0032743 |
|---|---|
| GO term | positive regulation of interleukin-2 production |
| Ontology | biological_process |
| Synonym | activation of interleukin-2 production; positive regulation of IL-2 production; positive regulation of interleukin-2 biosynthetic process; positive regulation of interleukin-2 secretion; stimulation of interleukin-2 production; up regulation of interleukin-2 production; up-regulation of interleukin-2 production; upregulation of interleukin-2 production |
| Major function | Increases the synthesis and secretion of IL-2, a key T cell growth factor, thereby promoting T cell activation, proliferation, and effector functions. |
| Related GO terms | regulation of interleukin-2 production (GO:0032673); positive regulation of T cell activation (GO:0050870); interleukin-2 production (GO:0032623) |
| Cellular location | Nucleus (transcription), cytoplasm (mRNA processing), endoplasmic reticulum/Golgi (secretion) |
| Key regulators | NF-κB, NFAT, AP-1, mTOR, CD28, IL-2R signaling |
What Is GO:0032743?
GO:0032743, positive regulation of interleukin-2 production, is defined as any process that activates or increases the frequency, rate, or extent of interleukin-2 production. This includes transcriptional activation of the IL2 gene, enhanced mRNA stability, increased translation, and augmented secretion of the mature cytokine. The term is a child of positive regulation of cytokine production and is specific to IL-2, distinguishing it from general immune activation processes.
Why Is positive regulation of interleukin-2 production Important in Cell Biology?
Positive regulation of IL-2 production is a cornerstone of adaptive immunity. IL-2 drives clonal expansion of antigen-specific T cells and is essential for the development of regulatory T cells and memory T cells. Its dysregulation is linked to autoimmune diseases such as type 1 diabetes and multiple sclerosis, where excessive IL-2 production contributes to tissue damage. Conversely, insufficient IL-2 production leads to immunodeficiency and impaired tumor surveillance. Understanding the molecular mechanisms that positively regulate IL-2 production can inform the design of immunotherapies, including CAR-T cells and cytokine-based treatments.
• IL-2 is required for T cell proliferation and survival; its positive regulation ensures robust immune responses.
• IL-2 promotes the differentiation of effector T cells and memory T cells, critical for long-term immunity.
• Positive regulation of IL-2 production is exploited in cancer immunotherapy to boost anti-tumor T cell activity.
• Dysregulated IL-2 production is associated with autoimmune diseases such as lupus and rheumatoid arthritis.
• IL-2 signaling influences T cell exhaustion, a major barrier in chronic infections and cancer.
• The process is modulated by co-stimulatory molecules like CD28 and cytokines like IL-1 and IL-6.
• Understanding IL-2 regulation aids in optimizing CAR-T cell therapies by managing CAR-negative T cell effects.
• IL-2 production is a biomarker for T cell activation in latent tuberculosis and other infections.
• Negative regulators such as TIM-3 and BLIMP1 provide checkpoints that can be targeted to enhance IL-2 production.
• CRISPR screens can identify novel regulators of IL-2 production, offering new therapeutic targets.
What Happens During positive regulation of interleukin-2 production?
T cell receptor and co-stimulatory signaling
In simple terms: When a T cell recognizes an antigen and receives a second signal, it turns on the IL-2 gene.
T cell receptor (TCR) engagement by antigen-MHC complexes, together with co-stimulation through CD28, activates a signaling cascade involving PLCγ, PKCθ, and calcium flux. This leads to activation of transcription factors such as NFAT, NF-κB, and AP-1, which bind the IL2 promoter and enhancer to initiate transcription. Without co-stimulation, T cells become anergic and fail to produce IL-2.
Transcriptional activation of the IL2 gene
In simple terms: Special proteins bind to the IL-2 gene and switch it on.
The IL2 promoter contains binding sites for NFAT, AP-1, NF-κB, and Oct-1. Upon T cell activation, NFAT is dephosphorylated by calcineurin and translocates to the nucleus, where it cooperates with AP-1 to drive IL2 transcription. NF-κB, activated via the IKK complex, also binds the IL2 promoter and enhances transcription. Positive regulation of IL-2 production thus requires coordinated action of multiple transcription factors.
Post-transcriptional and post-translational regulation
In simple terms: After the gene is turned on, the cell controls how much IL-2 protein is made and released.
IL-2 mRNA stability is regulated by AU-rich elements in its 3' untranslated region, which are targeted by RNA-binding proteins. Additionally, IL-2-mediated NF-κB-dependent mRNA splicing modulates interferon gamma production, indicating crosstalk between IL-2 signaling and other cytokine pathways. Secretion of IL-2 requires vesicular transport through the ER-Golgi pathway.
Feedback and negative regulation
In simple terms: The cell has brakes to prevent too much IL-2, which could be harmful.
Negative regulators such as TIM-3 and BLIMP1 suppress IL-2 production. TIM-3 engagement inhibits NFAT dephosphorylation and AP-1 transcription, reducing IL-2 production. BLIMP1 negatively regulates IL-2 signaling in T cells, acting as a feedback inhibitor. Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity. These checkpoints are crucial for preventing autoimmunity.
Integration with metabolic and environmental cues
In simple terms: The cell's energy status and environment also influence IL-2 production.
mTOR signaling integrates nutrient and energy signals to promote IL-2 production and T cell proliferation. Hypoxia, cytokines like IL-1 and IL-6, and costimulatory molecules further modulate IL-2 production. For example, IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor, linking environmental sensing to IL-2 production.
Key Genes Involved in GO:0032743 positive regulation of interleukin-2 production
The following genes and proteins are key players in the positive regulation of interleukin-2 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL2 | Encodes interleukin-2 cytokine | Target for overexpression or knockout to study IL-2 function |
| NFATC1 | Transcription factor activated by calcineurin; binds IL2 promoter | Knockout reduces IL-2 production; target for immunosuppressants |
| NFKB1 | Transcription factor; activates IL2 transcription | Knockout impairs IL-2 production; linked to inflammation |
| FOS | Component of AP-1; cooperates with NFAT | Knockout affects IL-2 production; studied in T cell activation |
| JUN | Component of AP-1; binds IL2 promoter | Knockout reduces IL-2; target for cancer and autoimmunity |
| CD28 | Co-stimulatory receptor; enhances IL-2 production | Knockout mice show impaired IL-2; target for immunotherapy |
| MTOR | Kinase; promotes IL-2 production via metabolic signaling | Inhibitors like rapamycin block IL-2; studied in transplantation |
| HAVCR2 | Encodes TIM-3; negative regulator of IL-2 production | Knockout increases IL-2; target for cancer immunotherapy |
| PRDM1 | Encodes BLIMP1; negative regulator of IL-2 signaling | Knockout enhances IL-2 responses; studied in autoimmunity |
| IKZF3 | Encodes Aiolos; represses IL-2 sensitivity | Knockout alters TFH and IL-2 responses; target in lupus |
| AHR | Aryl hydrocarbon receptor; mediates IL-2 effects on exhaustion | Knockout affects CD8+ T cell exhaustion; cancer immunotherapy target |
| RELA | NF-κB subunit; activates IL2 transcription | Knockout reduces IL-2; linked to NF-κB-dependent splicing |
| IL2RA | IL-2 receptor alpha chain (CD25); enhances IL-2 signaling | Knockout impairs Treg function; target for autoimmune therapy |
| IL2RB | IL-2 receptor beta chain; transduces signals | Knockout affects T cell proliferation; studied in immunodeficiency |
| IL2RG | Common gamma chain; shared by IL-2 family receptors | Mutations cause X-SCID; target for gene therapy |
| STAT5A | Transcription factor downstream of IL-2R; promotes IL-2 production | Knockout impairs T cell responses; studied in leukemia |
| STAT5B | Transcription factor downstream of IL-2R | Knockout affects Treg and IL-2 production; target in autoimmunity |
How Is positive regulation of interleukin-2 production Regulated?
Positive regulation of IL-2 production is controlled by a network of signaling pathways and transcription factors. The TCR/CD28 axis activates calcineurin-NFAT, PKCθ-NF-κB, and Ras-MAPK-AP-1 pathways, all of which converge on the IL2 promoter. mTOR signaling integrates metabolic cues to sustain IL-2 production. Negative feedback is provided by TIM-3, BLIMP1, and Aiolos, which suppress IL-2 production or sensitivity. Additionally, IL-2 itself can modulate its own production through feedback loops involving the aryl hydrocarbon receptor. Post-transcriptional mechanisms, including mRNA splicing and stability, further fine-tune IL-2 levels.
positive regulation of interleukin-2 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL2 | Autoimmunity, cancer immunotherapy | IL2 knockout mice; overexpression in T cells |
| HAVCR2 | Cancer, autoimmunity | TIM-3 knockout mice; point mutation in ligand-binding domain |
| PRDM1 | Autoimmunity, lymphoma | BLIMP1 knockout mice; conditional knockout in T cells |
| IKZF3 | Lupus, autoimmune cytopenias | Aiolos knockout mice; knock-in of patient mutations |
| AHR | Cancer, T cell exhaustion | AHR knockout mice; overexpression in CD8+ T cells |
Autoimmune diseases
Excessive IL-2 production contributes to the pathogenesis of autoimmune diseases such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. IL-2 promotes the expansion of autoreactive T cells and can break tolerance. Therapies targeting the IL-2 pathway, such as low-dose IL-2 to expand regulatory T cells, are being explored. Polymorphisms in IL2 and IL2RA are associated with susceptibility to autoimmune conditions.
Cancer and immunotherapy
In cancer, IL-2 production is critical for anti-tumor immunity. High-dose IL-2 is approved for metastatic melanoma and renal cell carcinoma, but toxicity limits its use. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor, suggesting that modulating IL-2 production could improve immunotherapy outcomes. CAR-T cell therapies also rely on IL-2 production for optimal expansion and persistence; CAR-negative T cells can influence this process.
Infectious diseases
IL-2 production is essential for controlling infections. In latent tuberculosis, single-cell cytokine gene expression correlates with disease status, highlighting IL-2 as a biomarker. Pathogens may evade immunity by suppressing IL-2 production. Understanding positive regulation of IL-2 production can inform vaccine design and host-directed therapies.
Immunodeficiency
Mutations in genes required for IL-2 production or signaling, such as IL2RG, cause severe combined immunodeficiency (SCID). Defective IL-2 production leads to impaired T cell proliferation and increased susceptibility to infections. Gene therapy approaches aim to restore IL-2 signaling in these patients.
From positive regulation of interleukin-2 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate IL-2 production? | Knockout of gene X in Jurkat or primary T cells followed by IL-2 ELISA |
| Does a specific point mutation in gene X affect IL-2 production? | Point mutation knock-in using CRISPR in T cell lines |
| Does overexpression of gene X enhance IL-2 production? | Overexpression of gene X via lentiviral transduction in primary T cells |
| Does gene X interact with the IL2 promoter? | Tagged knock-in of gene X with ChIP-seq or ATAC-seq |
| Does gene X affect IL-2 production in vivo? | Conditional knockout mice with immunization or tumor models |
| Can CRISPR screen identify novel regulators of IL-2 production? | Genome-wide CRISPR knockout library in Jurkat cells followed by IL-2 reporter assay |
How to Study the positive regulation of interleukin-2 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-2 protein levels | Quantifying IL-2 production in T cell cultures |
| Flow cytometry | Intracellular IL-2 and surface markers | Identifying IL-2-producing T cell subsets |
| RNA-seq | IL2 mRNA and transcriptome changes | Global gene expression analysis after T cell activation |
| ChIP-seq | Transcription factor binding at IL2 locus | Mapping NFAT, NF-κB, AP-1 binding sites |
| CRISPR screen | Genes affecting IL-2 production | Unbiased discovery of regulators |
| Reporter assay | IL-2 promoter activity | High-throughput screening of modulators |
| Proteomics | Protein interactions and signaling | Identifying IL-2 regulatory complexes |
| Single-cell cytokine profiling | IL-2 expression in individual cells | Correlating with disease status |
Transcriptional profiling
RNA-seq and single-cell RNA-seq can measure IL2 mRNA levels and identify co-regulated genes. Single-cell cytokine gene expression in peripheral blood cells correlates with latent tuberculosis status, demonstrating the utility of this approach. ATAC-seq and ChIP-seq can map chromatin accessibility and transcription factor binding at the IL2 locus.
Protein-level quantification
ELISA and flow cytometry are standard for measuring IL-2 protein in supernatants and intracellularly. Phospho-flow cytometry can assess signaling pathways upstream of IL-2 production. Mass spectrometry-based proteomics can identify interaction partners of IL-2 regulatory proteins.
Functional genomics screens
CRISPR knockout and activation screens coupled with IL-2 reporter assays enable unbiased discovery of positive regulators. For example, a genome-wide screen could identify genes whose knockout reduces IL-2 production. These screens are powerful for identifying novel therapeutic targets.
Imaging and reporter systems
IL-2 promoter-driven fluorescent reporters allow real-time monitoring of IL-2 production in living cells. Confocal microscopy can visualize NFAT nuclear translocation and IL-2 vesicle trafficking. These methods provide spatial and temporal resolution of the regulatory process.
How CRISPR Can Be Used to Study GO:0032743 positive regulation of interleukin-2 production
Knockout
CRISPR knockout of candidate genes (e.g., NFATC1, NFKB1) in Jurkat or primary T cells can determine whether they are required for IL-2 production. Knockout of negative regulators like HAVCR2 (TIM-3) increases IL-2 production, validating them as targets. EDITGENE provides custom knockout cell lines to study positive regulation of IL-2 production.
Point Mutation
Point mutations can dissect specific residues or regulatory elements. For example, mutating phosphorylation sites in NFAT or NF-κB can reveal their role in IL-2 production. CRISPR point mutation knock-in models allow precise editing of the IL2 promoter or enhancer to study regulatory variants associated with disease.
Knock-in
Knock-in of reporter genes (e.g., GFP) under the IL2 promoter enables real-time tracking of IL-2 production. Tagged knock-in of regulatory proteins (e.g., HA-tagged NFAT) facilitates ChIP-seq and proteomics. EDITGENE offers knock-in services for such applications.
Overexpression
Overexpression of positive regulators (e.g., CD28, IL2 itself) can enhance IL-2 production and boost T cell responses. CRISPR activation (CRISPRa) can upregulate endogenous genes to study their impact on IL-2 production. EDITGENE provides overexpression cell models to validate candidate genes.
How EDITGENE Supports positive regulation of interleukin-2 production Research
Researchers studying positive regulation of interleukin-2 production-related genes often need to determine whether a candidate gene is causally involved in IL-2 regulation, and to dissect the precise molecular mechanisms. EDITGENE offers a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-2 production research.
Frequently Asked Questions About positive regulation of interleukin-2 production
What is GO:0032743?
GO:0032743 is a Gene Ontology term for 'positive regulation of interleukin-2 production', describing any process that activates or increases the frequency, rate, or extent of IL-2 production.
What genes are involved in positive regulation of interleukin-2 production?
Key genes include IL2, NFATC1, NFKB1, FOS, JUN, CD28, MTOR, and negative regulators like HAVCR2 (TIM-3), PRDM1 (BLIMP1), and IKZF3 (Aiolos).
How is IL-2 production positively regulated?
IL-2 production is positively regulated by TCR and CD28 signaling, which activate transcription factors NFAT, NF-κB, and AP-1, as well as by mTOR and other metabolic pathways.
What diseases are associated with dysregulated IL-2 production?
Dysregulated IL-2 production is linked to autoimmune diseases (e.g., lupus, type 1 diabetes), cancer, and immunodeficiency.
What methods are used to study positive regulation of IL-2 production?
Common methods include ELISA, flow cytometry, RNA-seq, ChIP-seq, CRISPR screens, and reporter assays.
How can CRISPR be used to study IL-2 regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of candidate genes to test their role in IL-2 production.
What is the role of TIM-3 in IL-2 production?
TIM-3 is a negative regulator that suppresses IL-2 production by inhibiting NFAT dephosphorylation and AP-1 transcription.
How does BLIMP1 affect IL-2 signaling?
BLIMP1 negatively regulates IL-2 signaling in T cells, acting as a feedback inhibitor.
What is the significance of IL-2 in cancer immunotherapy?
IL-2 is used to boost anti-tumor T cell responses, and its regulation is critical for CAR-T cell efficacy.
Can IL-2 production be measured in single cells?
Yes, single-cell cytokine gene expression profiling can measure IL-2 in individual cells and correlate with disease status.
Conclusion
Positive regulation of interleukin-2 production (GO:0032743) is a fundamental process in immune activation, with far-reaching implications for health and disease. The interplay of transcription factors, signaling pathways, and negative feedback loops ensures appropriate IL-2 levels. Dysregulation contributes to autoimmunity, cancer, and immunodeficiency, making this pathway a prime therapeutic target. Advances in CRISPR technology and functional genomics are accelerating the discovery of novel regulators, offering new opportunities for immunotherapy and precision medicine.
References
- 1. Liu Y et al.. 2021. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor.. Nat Immunol 22(3):358-369 PMID: 33432230
- 2. Van Gelder RD et al.. 2025. Interleukin-2-mediated NF-κB-dependent mRNA splicing modulates interferon gamma protein production.. EMBO Rep 26(1):16-35 PMID: 39578552
- 3. Read KA et al.. 2023. Aiolos represses CD4(+) T cell cytotoxic programming via reciprocal regulation of T(FH) transcription factors and IL-2 sensitivity.. Nat Commun 14(1):1652 PMID: 36964178
- 4. Vir P et al.. 2015. Single-Cell Cytokine Gene Expression in Peripheral Blood Cells Correlates with Latent Tuberculosis Status.. PLoS One 10(12):e0144904 PMID: 26658491
- 5. Roy S et al.. 2025. BLIMP1 negatively regulates IL-2 signaling in T cells.. Sci Adv 11(29):eadx8105 PMID: 40680114
- 6. Lee MJ et al.. 2012. Down-regulation of interleukin-2 production by CD4(+) T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription.. Immunobiology 217(10):986-95 PMID: 22445722
- 7. Sierro-Martínez B et al.. 2025. Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.. J Transl Med 23(1):942 PMID: 40830482
- 8. Orozco Valencia A et al.. 2020. Interleukin-2 as immunotherapeutic in the autoimmune diseases.. Int Immunopharmacol 81:106296 PMID: 32058934
